Vaccine investment strategy

in page functions

Gavi’s Vaccine Investment Strategy determines which vaccines are made available to countries through our vaccine support programmes.

Every five years, Gavi takes stock of available and expected vaccines to develop a new Vaccine Investment Strategy (VIS). The VIS sets new priorities for our vaccine support programmes through in depth analysis and extensive consultations.

Gavi is currently developing a new VIS for its future 2021-2025 strategic period. The 2018 VIS follows three phases:

  • Phase one prepares the ground for the VIS by developing a decision-making process and analytical plan, identifying and categorising vaccine candidates, and setting out a first set of evaluation criteria.
  • Phase two shortlists vaccine candidates for use in routine immunisation programmes, and sets criteria for evaluating vaccine investments in epidemic response, and in inactivated polio vaccine (IPV).
  • Phase three: in the final phase, recommendations for new vaccine investments will be developed for the November 2018 Gavi Board meeting.

Vaccine candidates

In April 2017, WHO conducted a landscape analysis to identify candidate vaccines for consideration in the 2018 Gavi VIS. Agreed inclusion criteria included public health relevance to low- and middle-income countries and expected licensure by 2023.

The vaccines under consideration in the 2018 VIS fit into one of the following three categories:

  1. Vaccine investments for endemic disease prevention through routine immunisation
  2. Vaccine investments for epidemic preparedness
  3. IPV support, post-eradication.

For each vaccine, Gavi will identify and review the latest evidence against a set of evaluation criteria. Partners and external stakeholders are essential in helping to build our evidence base.


Category one: evaluation of vaccines for endemic diseases

In November 2017, the Gavi Board approved a first set of criteria to be used for evaluating the first category of vaccines (for endemic disease prevention).

Evaluation Criteria for vaccines for endemic disease prevention through routine immunisation


Evaluation criteria 

Potential indicators 

Ranking criteria

Health impact

Future deaths and cases averted

Economic impact

Financial risk protection

Equity and social protection impact

Gender, wealth, geography

Global health security impact

Epidemic potential, antimicrobial resistance (AMR)

Value for money

Cost per death and case averted

Secondary criteria

Other impact

Under-five deaths averted, DALYs averted, cost per DALY averted

Gavi comparative advantage

Market shaping need and catalytic effect

Broader health systems benefits

Opportunity to strengthen health system or vaccination time points

Implementation feasibility

Ease of supply chain integration, healthcare worker behaviour change, feasibility of vaccination time points, need for demand promotion

Alternate interventions

Current and future alternative interventions


Vaccine cost

Procurement cost

Operational cost

Operational cost

Additional implementation cost

Surveillance, technical assistance, etc.

Data sources will include peer-reviewed literature, expert and partner input, consultations and models and analytics developed for the VIS process. Gavi is currently reaching out to its stakeholders, including manufacturers, Vaccine Alliance constituencies and disease experts, to gather information for the analyses.

The evaluation criteria for vaccines for epidemic preparedness and the approach for assessing IPV, post-eradication - are under development and will be published after the next Board meeting in June 2018.

For further information on the VIS process, please contact

Please note that the contents of the page reflect decisions taken at the November 2017 Board meeting.


Want more information about the Vaccine Investment Strategy in 2013 or 2008, click here.

>54 million

Our support has contributed to immunising over 54 million children against rotavirus diarrhoea. By the end of 2016, 40 countries had introduced the vaccine with support from the Vaccine Alliance.


More facts...

close icon

modal window here